

### ABSTRACT OF THE DISCLOSURE

This invention is directed to methods for providing sustained  
systemic concentrations of therapeutic or prophylactic agents such as GABA  
5 analogs following oral administration to animals. This invention is also  
directed to compounds and pharmaceutical compositions that are used in  
such methods.

10

0972425-10504  
T0500T 524250

23